Conference abstractPublished 14 Jun 2018
Listeria based nanovaccines as therapeutic vaccines
Instituto de Investigación Marqués de Valdecilla, Spain
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Dendritic cell-based (DC-based) vaccines are promising immunotherapies for cancer. However, several factors, such as the lack of efficient targeted delivery and the sources and types of DCs, have limited the efficacy of DCs and their clinical potential. We propose an alternative nanotechnology-based vaccine platform with antibacterial prophylactic abilities that uses gold glyconanoparticles coupled to listeriolysin O 91–99 peptide (GNP-LLO91–99), which acts as a novel adjuvant for cancer therapy as well as therapeutic vaccine for cutaneous melanoma acting as a novel immunotherapy. GNP-LLO91–99 exhibited dual anti-tumour activities, namely, the inhibition of tumour migration and growth and adjuvant activity for recruiting and activating DCs, including those from melanoma patients. GNP-LLO91–99 nanoparticles caused tumour apoptosis and induced antigen and melanomaspecific cytotoxic Th1 responses (P≤0.5). They also cause tumour complete remission and survival improvement. GNP-LLO91-99 nanovaccines presented superior tumour rejection and survival benefits, when combined with anti-PD-1 or anti-CTLA-4 checkpoint inhibitors, predicting an improvement of these immunotherapies action. Studies with monocyte-derived DCs of patients with stage IIIB melanoma confirmed the ability of GNP-LLO91-99 nanovaccines to complement the action of check point inhibitors, not only reducing cell-death markers expression on DCs, but also potentiating DC antigen-presentation and production of Th1-Th12 cytokines. We propose that GNP-LLO91-99 nanovaccines function as immune stimulators and immune effectors and serve as safe cancer therapies, alone or in combination with other immunotherapies.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNanotechnology
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Carmen Alvarez-Dominguez”